Coordinatore | Steno Diabetes Center A/S
Organization address
address: Niels Steensens Vej 2 contact info |
Nazionalità Coordinatore | Denmark [DK] |
Totale costo | 6˙324˙277 € |
EC contributo | 4˙233˙869 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2013-INNOVATION-1 |
Funding Scheme | CP-FP |
Anno di inizio | 2013 |
Periodo (anno-mese-giorno) | 2013-09-01 - 2017-08-31 |
# | ||||
---|---|---|---|---|
1 |
Steno Diabetes Center A/S
Organization address
address: Niels Steensens Vej 2 contact info |
DK (Gentofte) | coordinator | 826˙755.00 |
2 |
BIOMAX INFORMATICS AG
Organization address
address: ROBERT KOCH STRASSE 2 contact info |
DE (PLANEGG) | participant | 673˙360.00 |
3 |
Philips GmbH
Organization address
address: Luebeckertordamm 5 contact info |
DE (Hamburg) | participant | 596˙952.00 |
4 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | participant | 557˙735.00 |
5 |
TURUN YLIOPISTO
Organization address
address: YLIOPISTONMAKI contact info |
FI (TURUN YLIOPISTO) | participant | 544˙296.00 |
6 |
SERVICIO MADRILENO DE SALUD
Organization address
address: PLAZA CARLOS TRIAS BERTRAN 7 contact info |
ES (MADRID) | participant | 430˙950.00 |
7 |
TERVEYDEN JA HYVINVOINNIN LAITOS
Organization address
address: MANNERHEIMINTIE 166 contact info |
FI (HELSINKI) | participant | 425˙548.00 |
8 |
Teknologian tutkimuskeskus VTT Oy
Organization address
address: Vuorimiehentie 3 contact info |
FI (Espoo) | participant | 178˙273.00 |
9 |
PHILIPS TECHNOLOGIE GMBH
Organization address
address: LUEBECKERTORDAM 5 contact info |
DE (HAMBURG) | participant | 0.00 |
10 |
TEKNOLOGIAN TUTKIMUSKESKUS VTT
Organization address
address: TEKNIIKANTIE 4 A contact info |
FI (ESPOO) | participant | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'The theme of this collaborative project is development and application of neuroimaging and bioinformatics tools to study lipid metabolism as a common pathogenic link between psychotic disorders and its metabolic co-morbidities. The overall objective is to identify, prioritize and evaluate multi-modal blood and neuroimaging markers with diagnostic potential for prediction and monitoring of psychotic disorders and associated metabolic co-morbidities. We aim to (1) optimise a multidisciplinary approach for combining positron emission tomography (PET) and magnetic resonance imaging (MRI) with metabolomics approaches, (2) develop a PET-method for exploring endocannabinoid pathways in early psychosis in longitudinal study setting, and (3) develop combined PET-MRI biomarker methodology for psychiatric disorders by studying neurotransmitter interactions with multiple PET scan and MRI sequences. The balance of two or more neurotransmitter systems may function as a novel biomarker in these disorders. The expected impacts are (1) etiopathogenic understanding, (2) new validated multi-modal markers for early disease detection and monitoring, (3) new tools for the identification of subjects who may benefit from specific treatment (4) discovery of new avenues for disease prevention and therapy, and (5) new tools and processes for applying brain imaging in personalised medicine. The consortium brings together clinicians, researchers and industry partners in the domains of psychiatry, neuroimaging, metabolic research, systems biology and bioinformatics.'
"Optimisation of the development of Poverty-Related-Diseases (PRD) vaccines by a transversal approach, addressing common gaps and challenges."
Read MoreTargeting Src-family tyrosine kinases in chronic autoimmune and inflammatory diseases
Read MoreAn inquiry into the health and safety at work; a European Union perspective
Read More